Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether tubeless PNL changes severe adverse events MCID: 50 per 1000 compared with standard PNL (very low certainty).
Totally tubeless PNL showed no clear difference in severe adverse events MCID: 50 per 1000 compared with standard PNL (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether SGLT‐2 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
It is very uncertain whether GLP‐1 analogues inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
It is very uncertain whether DPP‐4 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Galantamine plus risperidone may leads to higher adverse events (Side Effects Checklist) compared with placebo plus risperidone (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
Early leads to higher adverse events: cardiac‐rhythm disorder compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Neutrophils decreased ‐ compared with no adjunctive treatment (very low certainty).
Tixagevimab/cilgavimab showed no clear difference in serious adverse events within 6 monthsb compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ infection at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
Immediate treatment may leads to higher adverse events (control ‐ no treatment) compared with controls (low certainty).
Rotarix showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).